Skip Navigation


NDT Advance Access originally published online on March 1, 2005
Nephrology Dialysis Transplantation 2005 20(4):678-683; doi:10.1093/ndt/gfh720
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/4/678    most recent
gfh720v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schrier, R. W.
Right arrow Articles by Parikh, C. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schrier, R. W.
Right arrow Articles by Parikh, C. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Editorial Review

Comparison of renal injury in myeloablative autologous, myeloablative allogeneic and non-myeloablative allogeneic haematopoietic cell transplantation

Robert W. Schrier1 and Chirag R. Parikh2

1 Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, CO, USA, 2 Section of Nephrology, Yale University, School of Medicine, New Haven, CT, USA

Correspondence and offprint requests to: Robert W. Schrier, MD, Professor or Chirag R. Parikh MD, PhD. Department of Medicine, The University of Colorado Health Sciences Center, 4200 East Ninth Avenue B178, Denver, CO 80262, USA. Email: robert.schrier@uchsc.edu, chirag.parikh@yale.edu

Keywords: allogeneic; autologous; haematopoietic; myeloablative; stem cell transplantation

The first 150 words of the full text of this article appear below.



   Introduction
 
The term bone marrow transplantation has been replaced by the term haematopoietic cell transplantation (HCT). This is because the haematopoietic cells for transplantation now have several sources including bone marrow, cytopheresis of peripheral blood, and cord blood. HCT is now used to treat several haematological diseases (e.g., aplastic anaemia, ß-thalassemia) and malignancies which otherwise are incurable. There are at present three major HCT procedures—these are myeloablative autologous, myeloablative and non-myeloablative allogeneic HCT. A non-myeloablative procedure for autologous HCT has been described. Renal injury and acute renal failure (ARF) are common complications of each of these procedures which affect both the morbidity and mortality of the recipient patient. The incidence and severity of the renal injury, however, are quite different in the three varieties of HCT. The purpose of this review, therefore, is to discuss the unique features of renal injury in autologous, myeloablative and non-myeloablative allogeneic HCT.



   Autologous haematopoietic cell transplantation
 
With myeloablative autologous . . . [Full Text of this Article]



   Allogeneic myeloablative stem cell transplantation
 


   Non-myeloablative allogeneic haematopoietic stem cell transplantation
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?